Daily Sepsis Research Analysis
Analyzed 31 papers and selected 3 impactful papers.
Summary
Analyzed 31 papers and selected 3 impactful articles.
Selected Articles
1. Pharmacological targeting of the NLRP3 LRR domain with isothiazolinones overcomes CRID3-resistant inflammation.
High-throughput screening identified LOC14, an isothiazolinone NLRP3 inhibitor that binds near the LRR domain, inhibiting both CRID3-sensitive and -resistant NLRP3 variants. LOC14 demonstrated in vivo anti-inflammatory efficacy across mouse models including sepsis, and structure–activity analysis highlighted the isothiazol-3(2H)-one carbonyl as critical for activity.
Impact: This work reveals a new druggable pocket on NLRP3 (LRR domain) and overcomes a key translational barrier of MCC950-resistant variants, broadening therapeutic prospects for inflammasome-driven diseases including sepsis.
Clinical Implications: While preclinical, the identification of LRR-domain inhibitors that work in MCC950-resistant settings provides a viable path to next-generation NLRP3 therapeutics that could attenuate dysregulated inflammation in sepsis.
Key Findings
- LOC14, an isothiazolinone small molecule, selectively inhibits NLRP3 by binding to/near the LRR domain.
- LOC14 blocks both CRID3-responsive and CRID3-non-responsive hyperactive/gain-of-function NLRP3 variants.
- In vivo, LOC14 exerts anti-inflammatory activity in mouse models of colitis, sepsis, and psoriasis.
- Structure–activity indicates the isothiazol-3(2H)-one carbonyl oxygen is essential for inhibitory activity.
Methodological Strengths
- High-throughput screening coupled with mechanistic target mapping (domain-level binding).
- Multi-model in vivo validation including a sepsis model, supporting translational relevance.
Limitations
- Preclinical stage without human pharmacokinetic/safety data.
- Precise structural binding mode requires further biophysical or structural studies.
Future Directions: Resolve the co-structure of LOC14–NLRP3 LRR, optimize ADME and selectivity, and progress to GLP toxicity and early-phase clinical trials in inflammasome-driven conditions, including septic inflammation endotypes.
The NLRP3 inflammasome is a key driver in inflammatory, infectious, metabolic, and neurodegenerative diseases. Although the NLRP3 inhibitor CRID3 (also known as MCC950) exhibits potent activity, it cannot inhibit several hyperactive NLRP3 mutations associated with autoinflammatory syndromes and has not progressed clinically, underscoring the need for the development of new NLRP3 inhibitors. Through a high-throughput screening, we identified LOC14, an isothiazolinone-containing small molecule, as a selective NLRP3 in
2. SMAD4 Inhibits HO-1-Driven Ferroptosis Through Transcriptional Repression in Sepsis-Associated Acute Kidney Injury.
Ferroptosis is robustly activated in SA-AKI. SMAD4 binds the HO-1 promoter to repress its transcription, thereby limiting ferroptosis. SMAD4 overexpression reduces HO-1, alleviates ferroptosis, and improves renal function in CLP mice and LPS-exposed models, revealing a novel SMAD4–HO-1 regulatory axis.
Impact: Identifies a tractable transcriptional checkpoint for ferroptosis in SA-AKI, integrating redox biology with a concrete molecular target (SMAD4–HO-1) and demonstrating functional renal protection.
Clinical Implications: Suggests that modulating the SMAD4–HO-1 axis or downstream ferroptosis pathways could prevent or treat SA-AKI; highlights ferroptosis biomarkers as potential stratification tools in sepsis trials.
Key Findings
- Ferroptosis is markedly activated during SA-AKI progression with ROS accumulation, lipid peroxidation, elevated Fe2+, Δψm disruption, and HO-1 upregulation.
- SMAD4 directly binds the HO-1 promoter (ChIP-qPCR; dual-luciferase) and represses its transcription.
- SMAD4 overexpression reduces HO-1, alleviates ferroptosis, and improves renal function in CLP and LPS models.
- Spatial proteomics and functional assays support a SMAD4–HO-1 regulatory axis controlling ferroptosis.
Methodological Strengths
- Multi-modal evidence: spatial proteomics, ChIP-qPCR, dual-luciferase, in vivo CLP and in vitro LPS models.
- Clear mechanistic causality via genetic manipulation of SMAD4 with functional renal readouts.
Limitations
- Preclinical models; human validation of the SMAD4–HO-1 axis in SA-AKI is pending.
- Specificity and safety of therapeutically modulating SMAD4 require further study.
Future Directions: Validate the SMAD4–HO-1 axis in human sepsis cohorts, develop small-molecule or gene-based modulators, and test ferroptosis-guided therapeutic strategies in SA-AKI trials.
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is a frequent and severe complication in critically ill patients, yet effective targeted therapies are lacking. Ferroptosis has been implicated in various forms of organ injury, but its role in SA-AKI and underlying regulatory mechanisms remain unclear. METHODS: A SA-AKI mouse model was established using cecal ligation and puncture (CLP). Renal histopathology, kidney function assays, and spatial proteomics were employed to assess ferroptosis activation. In vivo and in vitro
3. TP53 links mitochondria-endoplasmic reticulum crosstalk and ferroptosis in septic cardiomyopathy: Protective modulation by nicorandil.
TP53 is a hub linking MAM remodeling, calcium dysregulation, oxidative stress, and ferroptosis in septic cardiomyopathy. Nicorandil significantly attenuates myocardial injury in vitro and in vivo, reducing lipid peroxidation and iron accumulation and restoring GPX4/SLC7A11; TP53 overexpression blunts nicorandil’s protection, whereas TP53 knockdown is protective.
Impact: Provides mechanistic rationale for repurposing nicorandil in septic cardiomyopathy and delineates TP53-centered subcellular stress pathways amenable to therapeutic targeting.
Clinical Implications: Supports evaluation of nicorandil as an adjunctive therapy for septic cardiomyopathy and highlights ferroptosis/MAM biomarkers (e.g., GPX4, SLC7A11) for patient stratification.
Key Findings
- TP53 expression and activity increase in SCM, associated with enhanced ER–mitochondria proximity, Ca2+ dysregulation, oxidative stress, and ferroptosis.
- Nicorandil reduces myocardial injury, lipid peroxidation, and iron accumulation, restoring GPX4 and SLC7A11 in vitro and in vivo.
- TP53 overexpression weakens nicorandil’s protective effects; TP53 knockdown alleviates LPS-induced injury.
- Ferrostatin-1 partially recapitulates nicorandil’s protection; combined ER stress modulation further improves Ca2+ homeostasis.
Methodological Strengths
- Integrated bioinformatics with genetic gain/loss-of-function and pharmacologic modulation across cell and rat models.
- Multi-parameter assessment of mitochondrial function, calcium handling, oxidative stress, and ferroptosis.
Limitations
- Preclinical data; clinical efficacy and dosing strategies for nicorandil in sepsis are untested.
- Potential off-target effects and hemodynamic interactions of nicorandil in septic shock require careful evaluation.
Future Directions: Prospective translational studies to assess nicorandil’s safety/efficacy in septic cardiomyopathy, and trials incorporating ferroptosis/MAM biomarkers for enrichment.
BACKGROUND: Septic cardiomyopathy (SCM) is a major contributor to sepsis-related mortality, with limited targeted therapies. Ferroptosis and mitochondria-associated endoplasmic reticulum membranes (MAMs) have emerged as important regulators of cardiac injury. TP53 can influence ferroptosis and MAM function, but its role in SCM remains unclear. This study investigated the involvement of TP53 in MAM-associated ferroptosis and the potential protective effects of nicorandil (Nic). METHODS: Bioinformatics analyses were performed to id